NDAINJECTIONINJECTABLEPriority Review
Approved
May 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
TENSILON (edrophonium chloride) by R-Pharm US. Approved for depression. First approved in 1951.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TENSILON (edrophonium chloride) is an injectable cholinesterase inhibitor approved in 1951 for the treatment of depression. The drug works by inhibiting acetylcholinesterase, thereby increasing acetylcholine levels in the central nervous system. It is administered via injection and represents a legacy product from the early era of psychiatric pharmacotherapy.
LOE Approaching
Product is in end-of-life phase with minimal commercial infrastructure; limited team expansion or hiring expected.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
TENSILON offers minimal career growth opportunity due to its end-of-life status and zero linked job openings. Employment with this product is likely limited to legacy portfolio management roles with flat or declining responsibilities.
Brand Manager
Worked on TENSILON at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.